Skip to main content

Advertisement

SpringerLink
Log in

Neurologic complications of cancer therapy

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

  • Although progress in cancer research is paralleled by the discovery and development of novel chemotherapeutic agents, the benefits of these agents are offset by their side-effect profiles. Of the numerous adverse effects associated with antineoplastic drugs, peripheral neuropathy is the most frequent and is often debilitating. This article reviews the treatment options—both primary and secondary—for neuropathic complications of cancer therapy.

  • Before a potentially neurotoxic chemotherapeutic regimen is started, patients should undergo 1) a baseline neurologic history for possible coexisting risk factors for neuropathy; 2) physical evaluation; and 3) if indicated, electrophysiologic testing, including nerve conduction studies and electromyography. Patients should be followed closely for the development of neuropathic signs and symptoms. When symptoms (eg, paresthesias or pain) or deficits (eg, weakness) develop, their severity and their effect on quality of life will determine whether the neurotoxic chemotherapy should be continued at a lower dose or discontinued. Neuropathic pain should be treated aggressively with a stepwise approach. The decision to initiate therapy should be guided first by the severity of pain and second by the convenience of dosing and the side-effect profile of the medication.

  • Specific antineuropathic pain therapy may begin with a tricyclic antidepressant (TCA), titrated to 100 to 150 mg/d, unless anticholinergic side effects appear before this dosage is reached. The TCA may be replaced by or supplemented with antiepileptic agents, such as gabapentin, which is attractive because of its rapid dose titration (maximum, 3600 mg/d) and minimal interaction with other medications.

  • In addition to pharmacologic therapies targeting symptom management, new therapies directed at preventing the onset or progression of neurotoxicity are desperately needed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Cavaletti G, Marzorati L, Bogliun G, et al.: Cisplatininduced peripheral neurotoxicity is dependent on total-dose intensity and single-dose intensity. Cancer 1992, 69:203–207.

    Article  PubMed  CAS  Google Scholar 

  2. van der HoopRG, van der BurgME, ten Bokkel Huinink WW, et al.: Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer 1990, 66:1697–1702.

    Article  PubMed  Google Scholar 

  3. Alberts DS, Noel JK: Cisplatin-associated neurotoxicity: can it be prevented? Anticancer Drugs 1995, 6:369–383. This is a comprehensive review of the drugs that have been tested for cytoprotection in platinum-associated neuropathy.

    Article  PubMed  CAS  Google Scholar 

  4. Anderson H, Wagstaff J, Crowther D, et al.: Comparative toxicity of cisplatin, carboplatin (CBDCA) and iproplatin (CHIP) in combination with cyclophosphamide in patients with advanced epithelial ovarian cancer. Eur J Cancer Clin Oncol 1988, 24:1471–1479.

    Article  PubMed  CAS  Google Scholar 

  5. Adams M, Kerby IJ, Rocker I, et al.: A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. The Swons Gynaecological Cancer Group. Acta Oncol 1989, 28:57–60.

    PubMed  CAS  Google Scholar 

  6. Heinzlef O, Lotz J, Roullet E: Severe neuropathy after high dose carboplatin in three patients receiving multidrug chemotherapy. J Neurol Neurosurg Psychiatry 1998, 64:667–669.

    PubMed  CAS  Google Scholar 

  7. Pace A, Bove L, Nistico C, et al.: Vinorelbine neurotoxicity: clinical and neurophysiological findings in 23 patients. J Neurol Neurosurg Psychiatry 1996, 61:409–411.

    Article  PubMed  CAS  Google Scholar 

  8. Arner S, Meyerson BA: Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988, 33:11–23.

    Article  PubMed  CAS  Google Scholar 

  9. Grond S, Radbruch L, Meuser T, et al.: Assessment and treatment of neuropathic cancer pain following WHO guidelines. Pain 1999, 79:15–20.

    Article  PubMed  CAS  Google Scholar 

  10. World Health Organization: Cancer Pain Relief—with a Guide to Opioid Availability, edn 2. Geneva: World Health Organization; 1996.

  11. McQuay HJ, Tramer M, Nye BA, et al.: A systematic review of antidepressants in neuropathic pain. Pain 1996, 68:217–227. This is an excellent, comprehensive, critical review of 21 randomized controlled studies evaluating the use of antidepressants (mostly tricyclic antidepressants [TCAs]) in the treatment of neuropathic pain. It confirms the efficacy of TCAs and also indirectly addresses the question of whether the cause of neuropathic pain affects responsiveness to TCAs. The efficacy of TCAs was demonstrable across a diverse spectrum of causes of neuropathic pain, including neuropathic pain of diabetic origin (13 studies), neuropathic pain in postherpetic neuralgia (three studies), atypical facial pain (two studies), and central pain (three studies).

    Article  PubMed  CAS  Google Scholar 

  12. Hunter JC, Gogas KR, Hedley LR, et al.: The effect of novel anti-epileptic drugs in rat experimental models of acute and chronic pain. Eur J Pharmacol 1997, 324:153–160.

    Article  PubMed  CAS  Google Scholar 

  13. Backonja M, Beydoun A, Edwards KR, et al.: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA 1998, 280:1831–1836. Like the study by Rowbotham et al. [14], this is a randomized double-blind placebo-controlled study (165 patients) of gabapentin, but the patients had neuropathic pain associated with diabetes. This study supports the use of gabapentin monotherapy as an effective first-line antineuropathic treatment and as an alternative to tricyclic antidepressants (TCAs) in patients in whom TCAs are ineffective or contraindicated.

    Article  PubMed  CAS  Google Scholar 

  14. Rowbotham M, Harden N, Stacey B, et al.: Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA 1998, 280:1837–1842. This large randomized double-blind placebo-controlled study of 229 patients with postherpetic neuralgia (PHN) showed that gabapentin is a viable first-line treatment in PHN. Gabapentin was effective in the treatment of pai and sleep interference associated with PHN, and it produced improvements in patient mood and quality of life. This was a placebo-controlled study, but a comparison with the historical literature suggests that gabapentin is at least as effective and as safe as TCAs in the treatment of PHN.

    Article  PubMed  CAS  Google Scholar 

  15. Leijon G, Boivie J: Central post-stroke pain—a controlled trial of amitriptyline and carbamazepine. Pain 1989, 36:27–36.

    Article  PubMed  CAS  Google Scholar 

  16. Kingery WS: A critical review of controlled clinical trials for peripheral neuropathic pain and complex regional pain syndromes. Pain 1997, 73:123–139. This author provides an extensive review of more than 90 controlled drug trials using 48 different treatments; neuropathic pain and complex regional pain syndromes are both included. Like the review by McQuay et al. [11], this paper provides corroboration for the effectiveness of tricyclic antidepressants in the treatment of neuropathic pain. It also identifies the treatments for which placebo-controlled studies are not available.

    Article  PubMed  CAS  Google Scholar 

  17. Jackson DVJr, McMahan RA, Pope EK, et al.: Clinical trial of folinic acid to reduce vincristine neurotoxicity. Cancer Chemother Pharmacol 1986, 17:281–284.

    Article  PubMed  Google Scholar 

  18. Jackson DVJr, Pope EK, McMahan RA, et al.: Clinical trial of pyridoxine to reduce vincristine neurotoxicity. J Neurooncol 1986, 4:37–41.

    Article  PubMed  Google Scholar 

  19. Haythornthwaite JA, Menefee LA, Heinberg LJ, et al.: Pain coping strategies predict perceived control over pain. Pain 1998, 77:33–39.

    Article  PubMed  CAS  Google Scholar 

  20. Turner JA, Clancy S: Strategies for coping with chronic low back pain: relationship to pain and disability. Pain 1986, 24:355–364.

    Article  PubMed  CAS  Google Scholar 

  21. Keefe FJ, Williams DA: A comparison of coping strategies in chronic pain patients in different age groups. J Gerontol 1990, 45:P161-P165.

    PubMed  CAS  Google Scholar 

  22. Lorig K, Chastain RL, Ung E, et al.: Development and evaluation of a scale to measure perceived selfefficacy in people with arthritis. Arthritis Rheum 1989, 32:37–44.

    Article  PubMed  CAS  Google Scholar 

  23. Rejeski WJ, Craven T, Ettinger WHJr, et al.: Self-efficacy and pain in disability with osteoarthritis of the knee. J Gerontol B Psychol Sci Soc Sci 1996, 51:P24-P29.

    PubMed  CAS  Google Scholar 

  24. Jensen MP, Karoly P: Control beliefs, coping efforts, and adjustment to chronic pain. J Consult Clin Psychol 1991, 59:431–438.

    Article  PubMed  CAS  Google Scholar 

  25. Max MB, Culnane M, Schafer SC, et al.: Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987, 37:589–596.

    PubMed  CAS  Google Scholar 

  26. Sindrup SH, Gram LF, Skjold T, et al.: Concentrationresponse relationship in imipramine treatment of diabetic neuropathy symptoms. Clin Pharmacol Ther 1990, 47:509–515.

    Article  PubMed  CAS  Google Scholar 

  27. Abdi S, Lee DH, Chung JM: The anti-allodynic effects of amitriptyline, gabapentin, and lidocain in a rat model of neuropathic pain. Anesth Analg 1998, 87:1360–1366.

    Article  PubMed  CAS  Google Scholar 

  28. Chapman V, Suzuki R, Chamarette HL, et al.: Effects of systemic carbamazepine and gabapentin on spinal neuronal responses in spinal nerve ligated rats. Pain 1998, 75:261–272.

    Article  PubMed  CAS  Google Scholar 

  29. Khan OA: Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology 1998, 51:611–614.

    PubMed  CAS  Google Scholar 

  30. Gould HJ: Gabapentin induced polyneuropathy. Pain 1998, 74:341–343.

    Article  PubMed  CAS  Google Scholar 

  31. Portenoy RK: Chronic opioid therapy for chronic nonmalignant pain: from models to practice. Am Pain Soc J 1992, 1:285–288.

    Google Scholar 

  32. Rowbotham MC, Reisner-Keller LA, Fields HL: Both intravenous lidocaine and morphine reduce the pain of postherpetic neuralgia. Neurology 1991, 41:1024–1028.

    PubMed  CAS  Google Scholar 

  33. Galer BS: Neuropathic pain of peripheral origin: advances in pharmacologic treatment. Neurology 1995, 45(suppl 9):S17-S25.

    PubMed  CAS  Google Scholar 

  34. Fields HL: Peripheral neuropathic pain: an approach to management. In Textbook of Pain. Edited by Wall PD, MelzackR. Edinburgh: Churchill Livingstone; 1994:919–995.

    Google Scholar 

  35. Rosen PS, Graham W: The shoulder-hand syndrome: historical review of observations on seventy-three patients. Can Med Assoc J 1957, 77:86–91.

    PubMed  CAS  Google Scholar 

  36. Poplawski ZJ, Wiley AM, Murray JF: Post-traumatic dystrophy of the extremities. J Bone Joint Surg [Am] 1983, 65A:642–655.

    Google Scholar 

  37. Morley S, Eccleston C, Williams A: Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. Pain 1998, 80:1–13.

    Article  Google Scholar 

  38. Gill JS, Windebank AJ: Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 1998, 101:2842–2850.

    Article  PubMed  CAS  Google Scholar 

  39. Hayakawa K, Sobue G, Itoh T, et al.: Nerve growth factor prevents neurotoxic effects of cisplatin, vincristine and taxol, on adult rat sympathetic ganglion explants in vitro. Life Sci 1994, 55:519–525.

    Article  PubMed  CAS  Google Scholar 

  40. Hayakawa K, Itoh T, Niwa H, et al.: NGF prevention of neurotoxicity induced by cisplatin, vincristine and taxol depends on toxicity of each drug and NGF treatment schedule: in vitro study of adult rat sympathetic ganglion explants. Brain Res 1998, 794:313–319.

    Article  PubMed  CAS  Google Scholar 

  41. Konings PN, Makkink WK, van DelftAM, et al.: Reversal by NGF of cytostatic drug-induced reduction of neurite outgrowth in rat dorsal root ganglia in vitro. Brain Res 1994, 640:195–204.

    Article  PubMed  CAS  Google Scholar 

  42. Apfel SC, Arezzo JC, Lipson L, et al.: Nerve growth factor prevents experimental cisplatin neuropathy. Ann Neurol 1992, 31:76–80.

    Article  PubMed  CAS  Google Scholar 

  43. Elias KA, Cronin MJ, Stewart TA, et al.: Peripheral neuropathy in transgenic diabetic mice—restoration of C-fiber function with human recombinant nerve growth factor. Diabetes 1998, 47:1637–1642.

    Article  PubMed  CAS  Google Scholar 

  44. Zochodn DW: Neurotrophins and other growth factors in diabetic neuropathy. Semin Neurol 1996, 16:153–161.

    Google Scholar 

  45. Rask CA: Biological actions of nerve growth factor in the peripheral nervous system. Eur Neurol 1999, 41:14–19.

    Article  PubMed  CAS  Google Scholar 

  46. Apfel SC, Kessler JA, Adornato BT, et al.: Recombinant human nerve growth factor in the treatment of diabetic polyneuropathy. NGF Study Group. Neurology 1998, 51:695–702. In this randomized placebo-controlled study of 250 patients with diabetic neuropathy, recombinant human nerve growth factor improved the results of 1) the sensory component of neurologic examination and 2) quantitative sensory testing.

    PubMed  CAS  Google Scholar 

  47. Gao WQ, Dybdal N, Shinsky N, et al.: Neurotrophin-3 reverses experimental cisplatin-induced peripheral sensory neuropathy. Ann Neurol 1995, 38:30–37.

    Article  PubMed  CAS  Google Scholar 

  48. Apfel SC: Neurotrophic factors and diabetic peripheral neuropathy. Eur Neurol 1999, 41:27–34.

    Article  PubMed  CAS  Google Scholar 

  49. Kemp G, Rose P, Lurain J, et al.: Amifostine pretreatment for protection against cyclophosphamideinduced and cisplatin-induced toxicities: results of a randomized control trial in patients with advance ovarian cancer. J Clin Oncol 1996, 14:2101–2112. This large randomized study showed that amifostine decreased neurotoxicity and ototoxicity without negating the antitumor effects of platinum.

    PubMed  CAS  Google Scholar 

  50. Apfel SC, Lipton RB, Arezzo JC, et al.: Nerve growth factor prevents toxic neuropathy in mice. Ann Neurol 1991, 29:87–90.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Mayo Clinic, 200 First Street SW, 55905, Rochester, MN, USA

    Joon H. Uhm MD

  2. Department of Neuro-Oncology, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 100, 77030, Houston, TX, USA

    W. K. Alfred Yung MD

Authors
  1. Joon H. Uhm MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W. K. Alfred Yung MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Uhm, J.H., Yung, W.K.A. Neurologic complications of cancer therapy. Curr Treat Options Neurol 1, 428–437 (1999). https://doi.org/10.1007/s11940-996-0006-x

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-996-0006-x

Keywords

Search

Navigation